Role of Calcium Binding Protein S100A12 in Diagnosis and Prognosis of Kawasaki Disease
Study Details
Study Description
Brief Summary
Recent studies showed that the value of c100A12 increased in children with Kawasaki disease, and decreased rapidly after treatment with gamma globulin. In kawasaki disease with coronary artery dilatation, S100A12 levels are elevated in the acute phase of Kawasaki disease and continue for some time in the convalescence phase before gradually decreasing. However, the number of patients included in previous studies was small and the follow-up time was short. In this study, 100 children with Kawasaki disease who were admitted to Wuhan Children's Hospital, Jingzhou First People's Hospital and Renhe Hospital affiliated to China Three Gorges University from December 2021 to December 2023 were selected as the research objects, and 100 children with healthy physical examination were selected as the control group during the same period. To investigate whether S100A12 increased significantly in the acute phase of Kawasaki disease compared with a healthy control group. To study whether S100A12 value increased rather than decreased in kawasaki disease that did not respond to gamma globulin treatment after gamma globulin treatment. At the same time, to study whether the increase of S100A12 in kawasaki disease convalescence indicates coronary aneurysm.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
S100A12 was determined using the ELISA kit and according to the instructions.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Kawasaki disease All children with Kawasaki disease met the diagnostic criteria for Kawasaki disease revised by the American Heart Association in 2017. |
Diagnostic Test: S100A12
The early dynamic detection of S100A12 was used to determine whether it was an auxiliary diagnostic index for Kawasaki disease
|
Healthy controls Healthy control group were healthy children who underwent outpatient physical examination. |
Diagnostic Test: S100A12
The early dynamic detection of S100A12 was used to determine whether it was an auxiliary diagnostic index for Kawasaki disease
|
Outcome Measures
Primary Outcome Measures
- S100A12 [From date of randomization until the date of first documented progression, whichever came first, assessed up to 18 months]
S100A12 was increased in children with Kawasaki disease and decreased after gamma globulin treatment
Secondary Outcome Measures
- CRP [From date of randomization until the date of first documented progression, whichever came first, assessed up to 18 months]
Measure the CRP value
Eligibility Criteria
Criteria
Inclusion Criteria:
â–ªDiagnostic criteria of Kawasaki disease revised by the American Heart Association in 2017
Exclusion Criteria:
-
Scarlet fever
-
Drug allergy syndrome
-
Stevens-Johnson syndrome
-
Toxic shock syndrome
-
Adenovirus infection
-
Epstein-Barr(EB) virus infection
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- The First Affiliated Hospital of Yangtze University
Investigators
- Principal Investigator: Qihong Fan, Dr., Yangtze University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PYan